New discoveries in melanoma, glioblastoma and bladder cancer

Here are a few highlights of cancer research news that have recently caught my attention:

  • Researchers at allied cancer institutes have found that patients with melanoma receiving the drug nivolumab had longer periods of remission.  The complete study is published in the Journal of Clinical Oncology.
  • Anti-psychotic drugs offer new hopes for patients with glioblastoma according to a study by researchers at the University of California, San Diego.
  • Researchers at the Dana Farber Institute have found an “exceptional” response from targeted drugs while treating a patient with advanced bladder cancer.  The study is published in the journal Cancer Discovery.

Please feel free to contact Marisol Hernandez for comments on the latest cancer research news.

Enhanced Figure Viewing in PLOS ONE

PLOS ONE now offers the ability to enlarge a figure to nearly your computer’s screen size so you can examine the minute details of a given figure and zoom-in and -out. The ability to easily click “in context” allows readers to see the image alongside relevant text and understand what the author is trying to show by including this particular image in his/her research article.

A good article to test this out on is one on transcription factors of Hydrozoan Jellyfish. Scroll down to the box where the figures appear, choose the one with the actual photos or internal snapshots of jellyfish, and use the zoom function at the bottom of the screen to take a close look at the pictures. You’ll notice that the high definition images do not pixelate or blur as you get closer.

Just another reason to check out this Open Access resource for up-to-date information and publications in your field.

ILLiad Document Delivery Technical Problems

The ILLiad Document Delivery System is currently unavailable due to problems with the server. We are working to resolve this issue as soon as possible.

We ask that MSK staff members with critical requests please send citation information to ill@mskcc.org until this issue is resolved.

Thank you for your patience.